Alaunos Therapeutics, Inc.

Having an approved and marketed drug is not enough to keep a biopharmaceutical company alive in the current financing environment in which stock prices are down and public offerings are not viable fun

AstraZeneca PLC has kept a low profile in the oncology cell therapy space but efforts to catch up on its big pharma peers have been brewing since 2019 and have culminated in the acquisition of Neoge

Japanese bioventure Solasia Pharma K.K. 's Darvias (darinaparsin; SP-02) has received its first approval in Japan for the treatment of relapsed/refractory peripheral T-cell lymphoma (PTCL), marking t

To say that 2022 has gotten off to a rough start for investors that back biopharmaceutical companies would be an understatement. The Nasdaq Biotechnology Index (NBI) is down 14.3% year-to-date and the